C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
0
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960
Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
0
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
https://www.zacks.com/stock/news/2208400/sellas-sls-rises-on-fda-fast-track-tag-to-leukemia-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208400
Jan 10, 2024 - The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
0
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092
Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
0
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
https://www.zacks.com/stock/news/2206966/amicus-fold-issues-preliminary-revenue-results-for-fy23?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2206966
Jan 08, 2024 - Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
0
Best Momentum Stocks to Buy for January 3rd
https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2204746
Jan 03, 2024 - SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
0
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
https://www.zacks.com/stock/news/2202279/sarepta-srpt-seeks-label-expansion-for-dmd-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202279
Dec 26, 2023 - Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
0
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
https://www.fool.com/investing/2023/12/22/could-sarepta-therapeutics-be-the-next-vertex/?source=iedfolrf0000001
Dec 22, 2023 - Both develop medicines for rare diseases, and each aims to conquer a niche market.
0
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
https://www.zacks.com/stock/news/2201572/3-beaten-down-biotech-stocks-to-buy-for-a-turnaround-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2201572
Dec 22, 2023 - Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
0
Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2198730/wall-street-analysts-see-a-53-71-upside-in-sarepta-therapeutics-srpt-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2198730
Dec 15, 2023 - The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0